BPC-157 vs Wolverine Stack (BPC-157 + TB-500)

BPC-157

BPC-157 is a synthetic 15-residue peptide whose sequence was taken from a larger protein reported in human gastric juice. That parent protein, named body protection compound, is described mainly in the papers of the group that reported it, and the peptide is known almost entirely through its own studies. Most published work comes from that single research group and is in rodents, covering models of tendon, ligament, muscle and bone injury, lesions of the stomach and intestine, and some nervous-system models. Human data are very limited, consisting of a few small reports rather than controlled trials. Independent replication outside the originating group is limited.

Wolverine Stack (BPC-157 + TB-500)

This blend combines two synthetic peptides, BPC-157 and TB-500, supplied together as one product; it is not a new compound. BPC-157 is a 15-residue peptide whose sequence its originators describe as derived from a protein in gastric juice; almost all of its literature comes from rodent studies, much of it from a single research group, and human data are very limited. TB-500 is the synthetic seven-residue fragment Ac-LKKTETQ of thymosin β4, and most related research concerns the full-length 43-residue protein rather than the fragment. We are not aware of any published study that has tested the two peptides together, so the blend has no literature of its own.

How BPC-157 acts

No receptor for BPC-157 has been identified. Rodent and cell studies have reported changes in several signalling systems, most often the nitric oxide system, VEGF receptor 2 signalling in endothelial cells, and the FAK–paxillin pathway in cultured tendon fibroblasts. Other papers describe interactions with dopamine and serotonin systems in animal models. Several studies have also examined growth-factor and early-response gene expression in injured tissue. Because many of these findings come from a small number of laboratories, using different models, the mechanism is best regarded as unsettled rather than as a known pathway.

How Wolverine Stack (BPC-157 + TB-500) acts

The two components are reported to act through different pathways, and no interaction between them has been studied. BPC-157 has no identified receptor; rodent and cell studies have linked it to nitric oxide signalling, to the VEGFR2 pathway in endothelial cells and to focal adhesion kinase and paxillin in cultured tendon fibroblasts. TB-500 reproduces the central actin-binding motif of thymosin β4, which in the full-length protein binds monomeric G-actin and regulates the pool of unpolymerised actin; how far the short fragment shares that binding is not well established.

The records side by side

• Type: BPC-157, Pentadecapeptide; Wolverine Stack (BPC-157 + TB-500), Two-peptide blend
• Length: BPC-157, 15 amino acids; Wolverine Stack (BPC-157 + TB-500), not recorded
• Molecular weight: BPC-157, 1419.5 g/mol; Wolverine Stack (BPC-157 + TB-500), not recorded
• Molecular formula: BPC-157, C62H98N16O22; Wolverine Stack (BPC-157 + TB-500), not recorded

Reading a comparison

A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.